{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:43:23Z","timestamp":1788518603525,"version":"build-2803163510"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["DIGITAL HEALTH"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>As a result of the unprecedented challenges imposed by the COVID-19 pandemic on enrollment to cancer clinical trials, there has been an urgency to identify and incorporate new solutions to mitigate these difficulties. The concept of decentralized or hybrid clinical trials has rapidly gained currency, given that it aims to reduce patient burden, increase patient enrollment and retention, and preserve quality of life, while also increasing the efficiency of trial logistics. Therefore, the clinical trial environment is moving toward remote collection and assessment of data, transitioning from the classic site-centric model to one that is more patient-centric.<\/jats:p>","DOI":"10.1177\/20552076221099997","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T12:02:41Z","timestamp":1653480161000},"page":"205520762210999","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-1684","authenticated-orcid":false,"given":"Bego\u00f1a","family":"de las Heras","sequence":"first","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"},{"name":"Madrid Medical Doctors Association, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Daehnke","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-3309","authenticated-orcid":false,"given":"Kamal S","family":"Saini","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Harris","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Morrison","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5002-1748","authenticated-orcid":false,"given":"Ariel","family":"Aguilo","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isagani","family":"Chico","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vidal","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Marcus","sequence":"additional","affiliation":[{"name":"Labcorp Drug Development Inc., Burlington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"bibr1-20552076221099997","doi-asserted-by":"crossref","first-page":"64","DOI":"10.36401\/JIPO-20-X7","volume":"4","author":"Desai A","year":"2021","journal-title":"J Immuno Precis Oncol"},{"key":"bibr2-20552076221099997","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/GO.20.00346","volume":"6","author":"Saini KS","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"bibr3-20552076221099997","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-20-1364","volume":"26","author":"Tan AC","year":"2020","journal-title":"Clin Cancer Res"},{"key":"bibr4-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00275"},{"key":"bibr5-20552076221099997","first-page":"1","volume":"29","author":"Doherty G","year":"2020","journal-title":"Nat Cancer"},{"key":"bibr6-20552076221099997","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1158\/2159-8290.CD-21-0850","volume":"11","author":"Flaherty KT","year":"2021","journal-title":"Cancer Discov"},{"key":"bibr7-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156686"},{"key":"bibr8-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy221"},{"key":"bibr9-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk140"},{"key":"bibr10-20552076221099997","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/PPA.S104259","volume":"27","author":"Sacrist\u00e1n JA","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"bibr11-20552076221099997","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.3857"},{"key":"bibr12-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4553"},{"key":"bibr13-20552076221099997","unstructured":"Center for Information & Study on Research Participation (CISCRP). Perceptions & insights study. General perceptions and knowledge on clinical research, https:\/\/www.ciscrp.org\/wp-content\/uploads\/2019\/06\/2017-CISCRP-Perceptions-and-Insights-Study-Perceptions-and-Knowledge.pdf (2017, accessed 22 May 2021)."},{"key":"bibr14-20552076221099997","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2021.39.15_suppl.1527","volume":"39","author":"Haque W","year":"2021","journal-title":"In J Clin Oncol"},{"key":"bibr15-20552076221099997","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.clinthera.2017.03.018","volume":"5","author":"Hirsch IB","year":"2017","journal-title":"Clin Ther"},{"key":"bibr16-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1159\/000506418"},{"key":"bibr17-20552076221099997","first-page":"262","volume":"4","author":"Collyar D","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"bibr18-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2021.19"},{"key":"bibr19-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1896753"},{"key":"bibr20-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntaa105"},{"key":"bibr21-20552076221099997","doi-asserted-by":"publisher","DOI":"10.2174\/1574887116666210122160705"},{"key":"bibr22-20552076221099997","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000441553","volume":"18","author":"Lehrach H","year":"2015","journal-title":"Public Health Genomics"},{"key":"bibr23-20552076221099997","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpt.1441","volume":"106","author":"Khozin S","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"bibr24-20552076221099997","unstructured":"Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices. Guidance for industry and food and drug administration staff, https:\/\/www.fda.gov\/media\/99447\/download (2017, accessed 22 May 2021)."},{"key":"bibr25-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1638"},{"key":"bibr26-20552076221099997","unstructured":"Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA's new strategic framework to advance use of real-world evidence to support development of drugs and biologics. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-fdas-new-strategic-framework-advance-use-real-world (2018, accessed 22 May 2021)."},{"key":"bibr27-20552076221099997","unstructured":"Food and Drug Administration. Enhancing the diversity of clinical trial populations \u2014 eligibility criteria, enrollment practices, and trial designs. Guidance for the industry clinical\/medical, https:\/\/www.fda.gov\/media\/127712\/download (2020, accessed 22 May 2021)."},{"key":"bibr28-20552076221099997","unstructured":"Food and Drug Administration. Advancing oncology decentralized trials. Learning from covid-19 trial datasets, https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/advancing-oncology-decentralized-trials (2021, accessed 22 May 2021)."},{"key":"bibr29-20552076221099997","doi-asserted-by":"publisher","DOI":"10.2196\/19745"},{"key":"bibr30-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2017.0278"},{"key":"bibr31-20552076221099997","first-page":"1","volume":"2","author":"Dicker AP","year":"2018","journal-title":"JCO Clin Cancer Inform Actions"},{"key":"bibr32-20552076221099997","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0324"},{"key":"bibr33-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_320827"},{"key":"bibr34-20552076221099997","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00147","volume":"2","author":"Cox SM","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"bibr35-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200141"},{"key":"bibr36-20552076221099997","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00152","volume":"2","author":"Gupta A","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"bibr37-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-018-0032-6"},{"key":"bibr38-20552076221099997","first-page":"1","volume":"2","author":"Shivank Garg S","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"bibr39-20552076221099997","unstructured":"PharmaIntelligence Informa. Decentralized Clinical Trial in 2020, https:\/\/pharmaintelligence.informa.com\/resources\/productcontent\/2020\/07\/20\/10\/43\/sitecore\/shell\/\u223c\/media\/informa-shop-window\/pharma\/2020\/covid-24-campaign\/slides\/decentralized-clinical-trials-in-2020.pdf (2020, accessed 1 June 2021)."},{"key":"bibr40-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"bibr41-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa155"},{"key":"bibr42-20552076221099997","unstructured":"Center for Information & Study on Research Participation (CISCRP). Perceptions & insights study. General perceptions, https:\/\/www.ciscrp.org\/wp-content\/uploads\/2019\/12\/General-Perceptions-and-Awareness-Report-04DEC.pdf (2019, accessed 06 June 2021)."},{"key":"bibr43-20552076221099997","volume":"39","author":"De Paula BHR","year":"2021","journal-title":"In J Clin Oncol"},{"key":"bibr44-20552076221099997","doi-asserted-by":"publisher","DOI":"10.3390\/s17010130"},{"key":"bibr45-20552076221099997","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.10.015"},{"key":"bibr46-20552076221099997","volume":"38","author":"Jazieh AR","year":"2020","journal-title":"In J Clin Oncol"},{"key":"bibr47-20552076221099997","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/CCI.19.00128","volume":"4","author":"Gunturu KS","year":"2020","journal-title":"JCO Clin Cancer Inform"}],"container-title":["DIGITAL HEALTH"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552076221099997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552076221099997","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552076221099997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:51:15Z","timestamp":1777398675000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/20552076221099997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"alternative-id":["10.1177\/20552076221099997"],"URL":"https:\/\/doi.org\/10.1177\/20552076221099997","relation":{},"ISSN":["2055-2076","2055-2076"],"issn-type":[{"value":"2055-2076","type":"print"},{"value":"2055-2076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}